jRCT2061210069暂停不适用
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects with Moderate to Severe Psoriasis
AbbVie G.K.0 个研究点目标入组 200 人开始时间: 2022年4月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 发起方
- 入组人数
- 200
- 主要终点
- PASI 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 65age old under（—）
- 性别
- All
入选标准
- •Participants with stable moderate to severe plaque psoriasis of at least 6 months duration and who are candidates for systemic therapy or phototherapy.
排除标准
- •Primary non-responders to previous anti-IL-17 (e.g., secukinumab, ixekizumab, brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.
- •Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or
- •medication exacerbated psoriasis, or new onset guttate psoriasis or any other skin disease which may interfere with assessment of chronic plaque psoriasis.
结局指标
主要结局
PASI 75
时间窗: week16
Percentage of participants achieving >=75% reduction from baseline in Psoriasis Area Severity Index (PASI) score
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)jRCT2031220047AbbVie G.K.698
招募中
不适用
[M25-147] A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)jRCT2051250034AbbVie GK24
招募中
不适用
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants with Moderately to Severely Active Ulcerative Colitis.Ulcerative ColitisjRCT2011230031AbbVie G.K.110
招募中
2 期
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's DiseaseJPRN-jRCT2071230035Otani Tetsuya240
已完成
不适用
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaSchizophreniajRCT2031220096AbbVie G.K.250